Ipilimumab decreases chances of recurrence in Stage III Melanoma

Advanced melanoma patients who received adjuvant treatment with the checkpoint inhibitor (CTLA4) Ipilimumab had significantly increased overall survival, distant metastasis-free survival, and recurrence-free survival as compared with placebo, per a new study.

This is great news for melanoma patients since the new adjuvant treatment improves overall survival and has manageable toxicity levels. Until now, there have been comparatively fewer available treatment options.

Read more from the original article on MedPageToday

 

GenomePlan Mobile App

A Mobile App for Cancer Patients

Now available in the Apple App Store and via online patient portal at myviviphi.com

GenomePlan™ is a revolutionary mobile app built to help cancer patients learn more about their treatment options. Simple step-by-step prompts give patients the right treatment options to discuss with their doctor.

Patients can now build their own personalized treatment strategies which align with current nationally accepted standards of cancer care and new approaches to immunotherapy and targeted treatment.  The app guides patients through a series of straightforward questions – including cancer diagnosis, stage of diagnosis, and any identified tumor markers and gene alterations.

The artificial intelligence engine that drives the GenomePlan™ then generates personalized treatment plans so patients can make informed decisions with their doctors about the best treatment plan for their cancers.

PrecisionPlan for Oncology Professionals

Build Actionable, Patient-Specific Cancer Treatment Plans

Integrate or embed the Viviphi™ Artificial Intelligence Clinical Brain into your health system or cancer center EMR to make optimal, personalized, and patient-centered decisions.

Our codified clinical knowledge allows for expert-to-expert consultations and actionable patient-specific pathways built in seconds. 

PrecisionPlan™ is a comprehensive and continuum-based platform that outlines in detail the most appropriate clinical guidance in chemotherapy, immunotherapy, genomic-guided targeted therapy, anti-hormonal therapy, radiation therapy, surgery, supportive care, palliative care and follow up/survivorship that is unique to each patient.